Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Enliven Therapeutics, Inc.

ELVN ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$50.24

▲ +2.28%

Market Cap $3.68B · Vol 398.77K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.68B

Mid Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

-0.95%

YoY

RSI (14)

18.83

Momentum

Beta

0.21

vs Market

52W High

$62.32

21.18% below

52W Low

$14.83

231.22% above

Volume

398.77K

Avg 257.05K

P/B

1.99

Price-to-book

ROE

N/A

Return on equity

Free Float

84.25%

Public shares

Shariah Compliance8 STANDARDS

✗ Enliven Therapeutics, Inc. (ELVN) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ELVN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.65%

-15.61%

+11.99%

+80.78%

YTD

+226.23%

+164.14%

+212.05%

+194.15%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-103,694,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-25.86% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.99
P/FCF	N/A
EPS Growth	-0.95%
Outstanding Shares	73.27M

Technical Indicators

50-Day SMA	$56.32
200-Day SMA	$38.93
RSI (14)	18.83
Beta	0.21
52-Week High	$62.32
52-Week Low	$14.83

Volume Today	398.77K
Avg Daily Volume (30D)	257.05K
Relative Volume	1.55x
Volatility (10D)	44.88
Volatility (30D)	34.30
Free Float	84.25%

Analyst Consensus

BUY

Current Price $50.24

Mean Target $73.45

52W Low$14.83 52W High$62.32

Current

Target

$14.83 $62.32

Current Analyst target

+46.21% upside potential · 12 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00CP3BDF2

ISINUS29337E1029

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.49% ARGX.BR argenx SE +2.29% ARGX argenx SE +1.13% INSM Insmed Incorporated +1.14% 2269.HK WuXi Biologics (Cayman) Inc. +0.32%

Company Profile

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.